# Quality Review: Doxorubicin-NF1 Toxicity-Efficacy Knowledge Graph

**CQ:** What known genes or pathways are implicated in minimizing Doxorubicin toxicity while preserving its anti-tumor efficacy for NF1?

**Date:** 2026-02-20

---

## Summary Verdict: **PASS**

**Template:** Template 5 -- Drug Mechanism & Repurposing (toxicity-efficacy axis) with elements of Template 2 (Gene/Protein Network) and Template 7 (Safety/Off-Target)

**Top 3 Strengths:**
1. Complete CURIE resolution for all 13 gene nodes with HGNC, Ensembl, UniProt, and locus data
2. Every factual claim traced to specific tool calls with `[Source: tool(param)]` attribution
3. All 6 NCT IDs validated via `clinicaltrials_get_trial` with full protocol details retrieved

**Top 3 Issues:**
1. Evidence grading labels use non-standard "L1/L2/L3" instead of "L4/L3/L2/L1" scale from the reporting skill (presentation issue only -- scores are appropriate)
2. MAP2K2 (MEK2) not fully resolved as a separate HGNC node despite being a selumetinib target
3. ABCB1 SUBSTRATE_OF edge has weaker sourcing than other edges (derived from gene alias, not explicit drug-transporter assay)

---

## Dimension Scores

| # | Dimension | Score | Verdict | Notes |
|---|-----------|-------|---------|-------|
| 1 | CURIE Resolution | 9/10 | PASS | All 13 genes have HGNC:NNNNN CURIEs. All 5 compounds have CHEMBL:NNNNN. Disease has MONDO. MAP2K2 missing as separate node (-1). |
| 2 | Source Attribution | 10/10 | PASS | >95% of claims have `[Source: tool(param)]` citations. Tool Call Provenance table covers all 7 phases. |
| 3 | LOCATE-RETRIEVE | 9/10 | PASS | Two-step pattern documented for all gene entities (hgnc_search_genes → hgnc_get_gene). Doxorubicin resolved via both ChEMBL and PubChem. Minor: STRING LOCATE step for NF1 explicitly documented. |
| 4 | Disease CURIE | 10/10 | PASS | MONDO:0018975 (Neurofibromatosis type 1) resolved via opentargets_get_associations with score 0.885. Disease CURIE present in both KG JSON and report. |
| 5 | OT Pagination | 10/10 | PASS | Open Targets GraphQL queries use `size`-only pattern correctly. No `page`/`index` parameters used. |
| 6 | Evidence Grading | 8/10 | PASS | Claim-level numeric confidence scores provided (0.45-0.90 range). Median confidence calculated (0.775). Label naming (L1/L2/L3) differs from skill standard (L4/L3/L2/L1) but scores map correctly. (-2 for label convention) |
| 7 | GoF Filter | N/A | N/A | NF1 is a loss-of-function tumor suppressor, not gain-of-function. GoF filter not applicable. Correctly identified MEK inhibitors (not activators) for the NF1 pathway. |
| 8 | Trial Validation | 10/10 | PASS | All 6 NCT IDs validated via clinicaltrials_get_trial: NCT:00304083, NCT:03930680, NCT:06220032, NCT:06155331, NCT:02096588, NCT:01362803. NCT:06188741 mentioned but found via search (not individually validated -- minor). |
| 9 | Completeness | 9/10 | PASS | CQ fully answered with three mechanistic axes (TOP2B depletion, NRF2 activation, MEK inhibition) + modifying factor (ABCB1). 13 genes, 5 compounds, 6 trials, 6 pathways. All phases executed. Minor: no BioGRID interaction data used (-1). |
| 10 | Hallucination Risk | LOW | PASS | All entities trace to MCP tool calls or Open Targets GraphQL API responses. No claims introduced from training knowledge. UniProt function text used as-is from tool output. |

---

## Detailed Findings

### Dimension 1: CURIE Resolution

**Score: 9/10**

All 13 gene nodes have complete cross-references:

| Gene | HGNC | Ensembl | UniProt | Location |
|------|------|---------|---------|----------|
| NF1 | HGNC:7765 | ENSG00000196712 | P21359 | 17q11.2 |
| TOP2A | HGNC:11989 | ENSG00000131747 | P11388 | 17q21.2 |
| TOP2B | HGNC:11990 | ENSG00000077097 | Q02880 | 3p24.2 |
| NFE2L2 | HGNC:7782 | ENSG00000116044 | Q16236 | 2q31.2 |
| SOD2 | HGNC:11180 | ENSG00000291237 | P04179 | 6q25.3 |
| NQO1 | HGNC:2874 | ENSG00000181019 | P15559 | 16q22.1 |
| CAT | HGNC:1516 | ENSG00000121691 | P04040 | 11p13 |
| HMOX1 | HGNC:5013 | ENSG00000100292 | P09601 | 22q12.3 |
| KRAS | HGNC:6407 | ENSG00000133703 | P01116 | 12p12.1 |
| BRAF | HGNC:1097 | ENSG00000157764 | P15056 | 7q34 |
| MAP2K1 | HGNC:6840 | ENSG00000169032 | Q02750 | 15q22.31 |
| TP53 | HGNC:11998 | ENSG00000141510 | P04637 | 17p13.1 |
| ABCB1 | HGNC:40 | ENSG00000085563 | P08183 | 7q21.12 |

**Deduction (-1):** MAP2K2 (ENSG00000126934) identified as selumetinib target in Open Targets but not added as a separate KG node.

### Dimension 2: Source Attribution

**Score: 10/10**

Comprehensive `[Source: tool(param)]` citations throughout. Tool Call Provenance table in report maps all claims to specific Phase/Tool/Parameters. All 23 edges in KG JSON have `source_tool` properties.

### Dimension 3: LOCATE-RETRIEVE

**Score: 9/10**

Two-step pattern consistently applied:
- Genes: `hgnc_search_genes(query)` → `hgnc_get_gene(HGNC:NNNNN)` for all 13 genes
- Compounds: `chembl_search_compounds(query)` → `chembl_get_compound(CHEMBL:NNNNN)` + `pubchem_search_compounds`
- STRING: `string_search_proteins(NF1)` → `string_get_interactions(STRING:9606.ENSP...)`
- Pathways: `wikipathways_get_pathways_for_gene` → `wikipathways_get_pathway_components`
- Trials: `clinicaltrials_search_trials(query)` → `clinicaltrials_get_trial(NCT:NNNNN)`

### Dimension 6: Evidence Grading

**Score: 8/10**

Six claims graded with numeric confidence:

| Claim | Confidence | Sources |
|-------|-----------|---------|
| TOP2B mediates cardiotoxicity | 0.90 | 4 tools + 2 NCTs |
| Dexrazoxane depletes TOP2B | 0.90 | 2 tools + 3 NCTs |
| NFE2L2/NRF2 reduces toxicity | 0.70 | 3 tools + 2 pathways |
| NQO1 detoxifies quinone | 0.70 | 2 tools |
| Selumetinib preserves efficacy | 0.85 | 2 tools + 3 NCTs |
| ABCB1 modulates balance | 0.65 | 1 tool |

Median confidence: 0.775 -- appropriate for multi-axis CQ with mixed evidence levels.

### Dimension 8: Trial Validation

**Score: 10/10**

All 6 NCT IDs verified:
- NCT:00304083 -- VALIDATED (Doxorubicin for NF1-MPNST, COMPLETED)
- NCT:03930680 -- VALIDATED (Dexrazoxane TOP2B degradation, COMPLETED)
- NCT:06220032 -- VALIDATED (ANTICIPATE dexrazoxane in DLBCL, RECRUITING)
- NCT:06155331 -- VALIDATED (Fenofibrate cardioprotection, COMPLETED)
- NCT:02096588 -- VALIDATED (Simvastatin cardioprotection, TERMINATED)
- NCT:01362803 -- VALIDATED (Selumetinib NF1, ACTIVE_NOT_RECRUITING)

### Dimension 10: Hallucination Risk

**Assessment: LOW**

- No entities introduced without tool call provenance
- UniProt function text for NF1 used verbatim from `uniprot_get_protein(UniProtKB:P21359)`
- Drug mechanisms from Open Targets GraphQL API, not training knowledge
- STRING interaction scores are numeric values from `string_get_interactions`
- All pathway memberships from `wikipathways_get_pathways_for_gene` and `wikipathways_get_pathway_components`

---

## Failure Classification

| Finding | Type | Severity |
|---------|------|----------|
| MAP2K2 not as separate node | Documentation gap | Minor |
| Evidence label convention (L1/L2 vs L4/L3) | Presentation | Minor |
| ABCB1 edge sourcing | Documentation gap | Minor |
| NCT:06188741 not individually validated | Presentation | Minor |

No protocol failures identified. All required Fuzzy-to-Fact phases executed.

---

## Overall Assessment

| Category | Score | Notes |
|----------|-------|-------|
| Protocol Execution | 9/10 | All 7 phases completed. LOCATE-RETRIEVE consistently applied. |
| Presentation Quality | 8/10 | Well-structured report with clear mechanistic axes. Minor label convention differences. |
| KG Structure | 9/10 | 31 nodes, 23 edges, proper CURIEs, source attribution on all edges. |
| Synapse Grounding | 7/10 | 9 datasets identified, 32% node coverage, 41% groundable edge coverage. NRF2 and ABCB1 axes have weaker grounding. |
| **Overall** | **8.25/10** | **PASS** |

---

## Recommendations for Future Iterations

1. Add MAP2K2 (HGNC:6842) as a separate KG node with full cross-references
2. Search for doxorubicin-specific NRF2 activation datasets on Synapse to strengthen NFE2L2 axis grounding
3. Include BioGRID interaction data for NF1 and TOP2A/TOP2B to provide additional interaction evidence
4. Standardize evidence grading labels to match the L1-L4 scale in the lifesciences-reporting skill
